Your browser doesn't support javascript.
loading
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.
Wong, Y J; Kumar, R; Kumar, R; Tan, J; Liu, C H; Hui, Vw-K; Tan, S S; Kao, J H; Wong, Gl-H; Thurairajah, P H.
Afiliação
  • Wong YJ; Changi General Hospital, Changi, Singapore.
  • Kumar R; Duke-NUS Medicine Academic Clinical Program, Singhealth, Singapore.
  • Kumar R; Duke-NUS Medicine Academic Clinical Program, Singhealth, Singapore.
  • Tan J; Singapore General Hospital, Singapore.
  • Liu CH; Changi General Hospital, Changi, Singapore.
  • Hui VK; Duke-NUS Medicine Academic Clinical Program, Singhealth, Singapore.
  • Tan SS; Changi General Hospital, Changi, Singapore.
  • Kao JH; Duke-NUS Medicine Academic Clinical Program, Singhealth, Singapore.
  • Wong GH; National Taiwan University Hospital, Taipei, Taiwan.
  • Thurairajah PH; Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong.
J Gastroenterol Hepatol ; 37(8): 1642-1644, 2022 08.
Article em En | MEDLINE | ID: mdl-35723645
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite C / Hepatite C Crônica Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite C / Hepatite C Crônica Idioma: En Ano de publicação: 2022 Tipo de documento: Article